(Q87374722)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

editorial

0 references

title

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author

Paolo Antonio Ascierto

series ordinal

1

object named as

Paolo A Ascierto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Kim Margolin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

27 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

1617-1619

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Do BRAF inhibitors select for populations with different disease progression kinetics?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28622

7 January 2021

Identifiers

DOI

10.1002/CNCR.28622

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577788%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference